Oncology
1 drug is in development for NSCLC (Advanced Non-small Cell Lung Cancer).
- Companies
- 1
- Clinical trials
- 10
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the NSCLC (Advanced Non-small Cell Lung Cancer) pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| ALX2004 | ALX ONCOLOGY HOLDINGS INC (ALXO) |
About this indication
NSCLC (Advanced Non-small Cell Lung Cancer) context
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung (D002289)
Narrower concept of MeSH descriptor Non-Small Cell Lung Cancer
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
Frequently asked questions
How many drugs are in development for NSCLC (Advanced Non-small Cell Lung Cancer)?
BioSniper tracks 1 drug in development for NSCLC (Advanced Non-small Cell Lung Cancer) across 1 company.
How many clinical trials target NSCLC (Advanced Non-small Cell Lung Cancer)?
There are 10 clinical trials targeting NSCLC (Advanced Non-small Cell Lung Cancer) tracked by BioSniper.
What is the prevalence of NSCLC (Advanced Non-small Cell Lung Cancer)?
The estimated prevalence of NSCLC (Advanced Non-small Cell Lung Cancer) is approximately 75.0 per 100,000 population.